Is there a role for the no observed adverse effect level in safety pharmacology?


Journal

Journal of pharmacological and toxicological methods
ISSN: 1873-488X
Titre abrégé: J Pharmacol Toxicol Methods
Pays: United States
ID NLM: 9206091

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 26 05 2020
revised: 22 06 2020
accepted: 24 06 2020
pubmed: 1 9 2020
medline: 16 7 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

In nonclinical toxicology the highest dose or exposure without test article-related adverse effects, known as the No Observed Adverse Effect Level (NOAEL), is a variable that may be determined. In safety pharmacology the vast majority of the endpoints measured are quantitative numeric functional endpoints such as changes in heart rate, blood pressure or respiratory frequency, endpoints that are usually not assessed using a defined framework of adversity. Therefore, we asked the question: is there a role for the NOAEL in safety pharmacology? To help answer this question, we conducted a survey via the Safety Pharmacology Society. We found that within safety pharmacology there is no formal definition of adversity and no guidance on defining NOAEL. We also found, perhaps unsurprisingly, there is no agreed rubric for using a NOAEL in safety pharmacology and we learned that the NOAEL is not a requirement in order to progress a new investigational drug through the regulatory process. Thus, a summary label such as NOAEL lacks nuance and disregards context in relation to the nature and the severity of the safety pharmacology findings. Consequently, defining 'adversity' and determining a NOAEL in safety pharmacology studies are not recommended since the range of functional endpoints investigated do not conform to a binary 'toxic/non-toxic' rubric. Focusing on describing test article-related effects on safety pharmacology endpoints, using reasoned arguments as part of an integrated risk assessment, will ensure that the clinical pharmacologists and regulatory bodies see a clear description of relevant findings at each dose or exposure level.

Identifiants

pubmed: 32866658
pii: S1056-8719(20)30246-X
doi: 10.1016/j.vascn.2020.106917
pii:
doi:

Substances chimiques

Drugs, Investigational 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106917

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tomas Mow (T)

Novo Nordisk A/S, Copenhagen, Denmark. Electronic address: tojm@novonordisk.com.

Ninette K Andersen (NK)

Novo Nordisk A/S, Copenhagen, Denmark.

Nils Dragsted (N)

Novo Nordisk A/S, Copenhagen, Denmark.

Anders B Lassen (AB)

Novo Nordisk A/S, Copenhagen, Denmark.

Morten Laursen (M)

Novo Nordisk A/S, Copenhagen, Denmark.

Alan S Bass (AS)

Merck and Co Inc, Boston, USA.

Jean-Pierre Valentin (JP)

UCB Biopharma SPRL, Braine-l'Alleud, Belgium.

Carrie Markgraf (C)

Sunovion Pharmaceuticals Inc, Marlborough, USA.

Simon Authier (S)

Charles River Laboratories, Laval, Canada.

Theodore J Baird (TJ)

Charles River Laboratories, Mattawan, USA.

Siddhartha Bhatt (S)

Pfizer Inc, Groton, USA.

Martin Traebert (M)

Novartis Pharma AG, Basel, Switzerland.

Derek J Leishman (DJ)

Eli Lilly and Co, Indianapolis, USA.

David Jones (D)

Medicines and Healthcare Products Regulatory Agency (MHRA), London, United Kingdom.

Michael J Curtis (MJ)

King's College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH